Search results
Showing 46 to 60 of 80 results for lower urinary tract symptoms
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)
This evidence summary has been updated and replaced by NICE guideline CG97.
This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.
View quality statements for QS36Show all sections
Sections for QS36
- Quality statements
- Quality statement 1: Presentation with unexplained fever of 38°C or higher
- Quality statement 2: History and examination – recording of risk factors
- Quality statement 3: Laboratory reporting – differentiation of E. coli and non-E. coli organisms
- Quality statement 4: Information about recognising re-infection
- Update information
- About this quality standard
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)
This guidance has been updated and replaced by NICE healthtech guidance 578.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)
We have moved Medical technologies guidance 58 to become HealthTech guidance 578. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)
We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Urethrotech UCD for difficult or failed catheterisation (MIB116)
NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.
This guidance has been updated and replaced by NICE interventional procedures guidance 770.
This guidance has been updated and replaced by NICE interventional procedures guidance 737.
Clostridioides difficile infection: antimicrobial prescribing (NG199)
This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.